|
US2017296646A1
|
|
Attenuated zika virus constructs and uses thereof
|
|
WO2017040380A2
|
|
Engineered antibody fc variants
|
|
WO2016191695A2
|
|
Treatments for obligately intracellular infections
|
|
WO2016134361A1
|
|
Avicin d for use in the treatment of mantle cell lymphoma
|
|
CA2964467A1
|
|
Methods for generating engineered enzymes
|
|
US2016135891A1
|
|
Systems and methods for imaging and manipulating tissue
|
|
US2016078309A1
|
|
Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography
|
|
WO2015171723A1
|
|
Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
|
|
US2015290168A1
|
|
Class IIa HDAC inhibitors for the treatment of infection
|
|
WO2015130783A1
|
|
Sty peptides for inhibition of angiogenesis
|
|
US2014288418A1
|
|
Apparatus and methods for pathlength multiplexing for angle resolved optical coherence tomography
|
|
WO2014152961A2
|
|
Apparatus and methods for optical coherence tomography and two-photon luminescence imaging
|
|
US2015368628A1
|
|
Deimmunized gelonin molecules and therapies
|
|
US2014179624A1
|
|
Cytoprotective derivatives of avicin d and methods of making and using thereof
|
|
WO2014066590A1
|
|
Jam-c antibodies and methods for treatment of cancer
|
|
WO2014055836A2
|
|
Serine protease molecules and therapies
|
|
WO2014052588A1
|
|
Attenuated chikungunya virus
|
|
US2014017764A1
|
|
Method for engineering proteases and protein kinases
|
|
WO2013181613A1
|
|
Mirna for the diagnosis and treatment of autoimmune and inflammatory disease
|
|
WO2013126730A1
|
|
Derivatives of avicin d and methods of making and using thereof
|
